Pliant Therapeutics has dosed the first patient in its Phase 1b FORTIFY trial testing PLN-101095 combined with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic solid tumors. The oral drug targets integrins αvβ8 and αvβ1 to block TGF-β activation, which may overcome tumor resistance to immunotherapy. The trial includes patients with non-small cell lung cancer, clear cell renal carcinoma, and tumors with high mutational burden, with interim data expected in 2027. This development could offer a new treatment option for patients with limited responses to current immunotherapies.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
